FindTrial
Sign In

Study on the efficacy and mechanisms of traditional Chinese medicine in preventing and treating chronic obstructive pulmonary disease with osteopenia

Sub-topic 1 of "Innovative Team of TCM Prevention and Treatment of Complications of Chronic Airway Disease": Study on the curative effect and mechanism of TCM prevention and treatment of chronic obstructive pulmonary disease complicated with osteopenia.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001140
Enrollment
Unknown
Registered
2025-06-09
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease with Osteopenia

Interventions

Observation group:Administer the Bu Fei Yi Shen Jian Gu Formula in conjunction with conventional Western medicine
Control group:Conventional Western medicine treatment

Sponsors

Wangjing Hospital China Academy of Chinese Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for stable COPD; 2. Meet the diagnostic criteria for osteopenia; 3. Present with TCM syndromes of lung - and kidney - qi deficiency combined with blood stasis; 4. Aged 75 or younger; 5. Willing to participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with severe primary diseases of the cardiocerebrovascular, renal, hepatic, or hematopoietic systems, or with malignant tumors or psychiatric disorders. 2. Women within 10 years of menopause. 3. Secondary osteoporosis caused by serious primary diseases, such as endocrine disorders (e.g., hyperthyroidism, diabetes, rheumatism), renal, nutritional, hematological, drug - induced, disuse, or congenital factors. 4. Patients with osteopenia who need anti - osteoporosis medication as per guidelines, such as those with a history of fragility fractures in the proximal humerus, distal forearm, or pelvis, or with a 10 - year hip fracture risk =3% or a 10 - year risk of other major osteoporotic fractures =20% as calculated by FRAX. 5. Patients who have used glucocorticoids, antiepileptics, or drugs affecting calcium, phosphorus, and bone metabolism within the past 6 months. 6. Patients allergic to or unable to tolerate any intervention in this study.

Design outcomes

Primary

MeasureTime frame
Bone density;—

Secondary

MeasureTime frame
Inflammatory factors;TCM Symptom Scoring;Lung function;Bone metabolism markers;Wnt-3a ß-catenin eggs;—

Countries

China

Contacts

Public ContactWang Bin

Wangjing Hospital of the Chinese Academy of Traditional Chinese Medicine

wjyyhxkwb@163.com13146098570

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026